At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
Ascorbic Acid +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating Ascorbic Acid, Paclitaxel protein-bound, and 2 other interventions for Pancreatic Cancer and 4 related conditions. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The purpose of this study is to see if a treatment regimen with a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma, Pancreas Metastases
CountriesUnited States
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartDec 2017
First PostedJan 2018
Primary CompletionSep 2021
Study CompletionJan 2022
TodayJul 2026
First PostedJan 25, 2018
Enrollment StartDec 15, 2017
Primary CompletionSep 14, 2021
Study CompletionJan 10, 2022
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 8.4 years ago
Interventions
Ascorbic Aciddrug
combination therapy
Paclitaxel protein-bounddrug
combination therapy
Cisplatindrug
combination therapy
Gemcitabinedrug
combination therapy